A first prescription fill can feel like the finish line for a pharma marketing campaign. The patient saw a message, talked with a healthcare provider, received a prescription, and picked up the medication. Success, right? Not necessarily. For marketers focused on sustainable brand growth, paid persistency helps show what happens after that initial conversion. A first fill may look impressive on a dashboard, yet affordability, coverage issues, treatment experience, or access friction can prevent the patient from reaching fill two. Therefore, measuring acquisition without examining downstream behavior can give marketers an incomplete picture of campaign performance.
Table of Contents
- Why first-fill metrics can be misleading
- What patient persistence tells pharma marketers
- Connecting marketing, access, and patient behavior
- Building campaigns around durable treatment starts
- Conclusion
- Frequently Asked Questions
Why First-Fill Metrics Can Tell an Incomplete Story
Pharma marketers have good reasons to monitor new prescriptions and first fills. These metrics help teams understand whether awareness and HCP engagement are translating into treatment starts. However, they do not automatically show whether those starts become sustained treatment.
The gap matters because patients face barriers throughout the prescription journey. Cost sharing is one of the clearest examples. IQVIA research on cost sharing has shown that prescription abandonment rises as patients face higher out-of-pocket costs.
Meanwhile, the challenge can continue after treatment begins. A patient may successfully complete the first fill and then encounter a higher-than-expected cost, an insurance change, a refill problem, pharmacy friction, or a treatment concern.
Consequently, a campaign optimized only around initial conversion may overstate its commercial impact. The marketing generated a treatment start, but did it help attract patients who could successfully continue therapy?
That distinction changes the measurement conversation. Instead of asking only how many patients converted, marketers can examine what happened to those patients afterward. That is where persistence data becomes especially useful, connecting patient acquisition with downstream treatment behavior.
What Patient Persistence Reveals About Long-Term Value
Paid persistency looks beyond the initial claim to show whether patients continue filling their prescriptions over time. In simple terms, it helps answer a critical commercial question: Did the treatment start last?
That question can uncover differences hidden by traditional acquisition metrics. Two campaigns, audiences, or channels might generate similar first-fill volumes. However, one could produce substantially stronger second-fill and subsequent refill behavior.
In that situation, treating both campaigns as equally successful would miss an important part of their value. The number of patients who start treatment matters, but what those patients do next can provide a much clearer picture of campaign quality.
Research also supports the importance of looking beyond initiation. For example, a study of specialty pharmacy services found a 17.5% increase in the rate of obtaining a second fill among new-to-therapy patients under the evaluated service model compared with matched controls.
Likewise, patient support can influence what happens after initiation. One study involving adalimumab found that patients participating in a support program had higher odds of a subsequent refill after the first prescription fill.
For marketers, continued prescription activity can therefore provide a valuable signal about the quality of those treatment starts. Rather than viewing every first fill as an equal outcome, teams can examine which campaigns and audiences are associated with stronger continuation.
Connecting Pharma Marketing Performance With Patient Access
A patient does not experience marketing, access, affordability, and support as separate organizational functions. Instead, those elements form one treatment journey. Pharma measurement strategies increasingly need to reflect that reality.
Consider a campaign that generates strong engagement and new prescriptions. If many patients subsequently encounter prior authorization problems, high costs, or pharmacy friction, the campaign’s first-fill results may not translate into durable brand performance.
Access barriers can be substantial. In addition, affordability can create another major break in the journey. Research has consistently associated higher patient cost sharing with lower medication initiation and, in many cases, reduced treatment persistence.
Therefore, persistence data is better used as a downstream performance signal that helps marketers ask better questions. It can reveal where commercially valuable patient journeys remain intact and where they begin to break down.
That insight can also shape media strategy. Teams can compare channels, audiences, and messages based on what patients do after the first fill, not simply how many patients start treatment. As a result, marketers can look beyond low-cost acquisition and identify campaigns associated with stronger treatment continuation.
For pharma organizations developing digital engagement and measurement strategies, eHealthcare Solutions offers additional perspectives on reaching healthcare audiences through digital marketing.
Building Pharma Campaigns Around Durable Treatment Starts
The next evolution of pharma marketing measurement is not about abandoning first-fill metrics. Rather, it is about placing them within the larger patient journey.
Start by connecting exposure and engagement data with prescription activity wherever privacy-safe measurement allows. Then evaluate new prescriptions, paid first fills, second fills, refill behavior, and longer-term treatment persistence.
Next, segment those outcomes. A campaign with a lower initial conversion rate could ultimately generate stronger value if its patients demonstrate better continuation. Conversely, a high-volume acquisition source may deserve closer examination when large numbers of patients disappear after fill one.
Marketers should also examine the timing of drop-off. Early discontinuation may point toward different barriers than attrition several months into treatment. Therefore, measuring persistence at several meaningful intervals can provide a clearer view than relying on one distant endpoint.
Most importantly, teams should avoid assuming that marketing alone causes persistence. Clinical factors, treatment effectiveness, tolerability, patient preference, affordability, insurance coverage, and provider decisions can all affect continuation. Persistence data is better used as a downstream performance signal that helps marketers understand these patterns without overstating advertising’s role.
When measurement combines acquisition with patient continuation, the definition of a successful campaign becomes more meaningful. Success is no longer simply generating a prescription or even a first paid claim. Instead, marketers can evaluate whether engagement is associated with patients successfully moving deeper into the treatment journey.
Conclusion
A first fill remains an important milestone, but it should not automatically be treated as proof of lasting campaign success. Patients can encounter significant barriers after treatment begins, and those barriers can reshape the commercial value of an initial conversion.
Looking at paid persistency gives pharma marketers a broader view of campaign performance. By connecting acquisition metrics with second fills, subsequent refills, and longer-term patient behavior, teams can better understand whether marketing is associated with durable treatment starts.
Ultimately, the question is not simply, “Did the patient fill?” It is also, “What happened next?” For brands seeking sustainable growth, that second question may be the more valuable one.
Frequently Asked Questions
What is paid persistency?
Paid persistency tracks whether patients continue to have paid prescription claims after starting therapy. It helps marketers and commercial teams evaluate treatment continuation beyond the initial fill.
Why should pharma marketers measure second fills?
A second fill provides an early indication that a treatment start continued beyond initial conversion. However, marketers should evaluate it alongside longer-term persistence and other patient journey measures.
Is paid persistency the same as medication adherence?
No. Persistence generally describes how long a patient continues therapy, while adherence examines how closely medication use follows the prescribed regimen. The measures can complement each other, but they answer different questions.
Can pharma marketing influence treatment persistence?
Marketing may contribute by connecting appropriate audiences with relevant education and support. However, treatment persistence also depends on clinical, financial, access, insurance, and patient-level factors. Marketers should avoid attributing persistence to advertising alone.
How can pharma brands use persistence data to improve campaigns?
Brands can compare downstream persistence across audiences, channels, campaigns, and patient segments using appropriate privacy-safe measurement. These insights can help identify acquisition sources associated with stronger long-term patient value rather than first-fill volume alone.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
